Literature DB >> 16794387

Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication: a randomized trial.

Werner A Draaisma1, Hilda G Rijnhart-de Jong, Ivo A M J Broeders, Andre J P M Smout, Edgar J B Furnee, Hein G Gooszen.   

Abstract

OBJECTIVE: The purpose of this prospective study was to compare the subjective and objective outcome of laparoscopic (LNF) and conventional Nissen fundoplication (CNF) up to 5 years after surgery as obtained in a multicenter randomized controlled trial. SUMMARY OF BACKGROUND DATA: LNF is regarded as surgical treatment of first choice for refractory gastroesophageal reflux disease by many surgeons based on several short- and mid-term studies. The long-term efficacy of Nissen fundoplication, however, is still questioned as objective data gathered from prospective studies are lacking.
METHODS: From 1997 to 1999, 177 patients were randomized to undergo LNF or CNF. Five years after surgery, all patients were requested to fill in questionnaires and to undergo esophageal manometry and 24-hour pH-metry.
RESULTS: A total of 148 patients agreed to participate in the follow-up study: 79 patients after LNF and 69 after CNF. Of these, 97 patients (48 LNF, 49 CNF) consented to undergo esophageal manometry and 24-hour pH-metry. At 5 years follow-up, 20 patients had undergone reoperation: 12 after LNF (15%) and 8 after CNF (12%). There was no difference in subjective outcome, with overall satisfaction rates of 88% and 90%, respectively. Total esophageal acid exposure times (pH < 4) were 2.1% +/- 0.5% and 2.0% +/- 0.6%, respectively (P = 0.21). Antisecretory medication was taken daily in 14% and 16%, respectively (P = 0.29). There was no correlation between medication use and acid exposure and indices of symptom-reflux association (symptom index and symptom association probability). No significant differences between subjective and objective results at 3 to 6 months and results obtained at 5 years after surgery were found.
CONCLUSIONS: The effects of LNF and CNF on general state of health and objective reflux control are sustained up to 5 years after surgery and the long-term results of LNF and CNF are comparable. A substantial minority of patients in both groups had a second antireflux operation or took antisecretory drugs, although the use of those medications did not appear to be related to abnormal esophageal acid exposure.

Entities:  

Mesh:

Year:  2006        PMID: 16794387      PMCID: PMC1570591          DOI: 10.1097/01.sla.0000217667.55939.64

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  38 in total

Review 1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

Authors:  D Moher; K F Schulz; D Altman
Journal:  JAMA       Date:  2001-04-18       Impact factor: 56.272

2.  Five- to eight-year outcome of the first laparoscopic Nissen fundoplications.

Authors:  T Bammer; R A Hinder; A Klaus; P J Klingler
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

3.  Randomized clinical trial of laparoscopic versus open fundoplication: blind evaluation of recovery and discharge period.

Authors:  G Nilsson; S Larsson; F Johnsson
Journal:  Br J Surg       Date:  2000-07       Impact factor: 6.939

4.  Short-term outcome after laparoscopic and open 360 degrees fundoplication. A prospective randomized trial.

Authors:  J Wenner; G Nilsson; S Oberg; T Melin; S Larsson; F Johnsson
Journal:  Surg Endosc       Date:  2001-10       Impact factor: 4.584

5.  Examining the learning curve of laparoscopic fundoplications at an urban community hospital.

Authors:  Hamish Hwang; Laurence J Turner; N Peter Blair
Journal:  Am J Surg       Date:  2005-05       Impact factor: 2.565

6.  Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group.

Authors:  J E Bais; J F Bartelsman; H J Bonjer; M A Cuesta; P M Go; E C Klinkenberg-Knol; J J van Lanschot; J H Nadorp; A J Smout; Y van der Graaf; H G Gooszen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

7.  Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial.

Authors:  T J Heikkinen; K Haukipuro; S Bringman; S Ramel; A Sorasto; A Hulkko
Journal:  Surg Endosc       Date:  2000-11       Impact factor: 4.584

8.  [Quality of life and subjective evaluation of outcome quality 3 years after laparoscopic antireflux surgery].

Authors:  F A Granderath; T Kamolz; U M Schweiger; T Bammer; R Pointner
Journal:  Chirurg       Date:  2000-08       Impact factor: 0.955

9.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.

Authors:  S J Spechler; E Lee; D Ahnen; R K Goyal; I Hirano; F Ramirez; J P Raufman; R Sampliner; T Schnell; S Sontag; Z R Vlahcevic; R Young; W Williford
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

10.  Laparoscopic Nissen fundoplication: five-year results and beyond.

Authors:  T Lafullarde; D I Watson; G G Jamieson; J C Myers; P A Game; P G Devitt
Journal:  Arch Surg       Date:  2001-02
View more
  43 in total

Review 1.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

2.  Histopathology of columnar-lined esophagus in patients with gastroesophageal reflux disease.

Authors:  Johannes Lenglinger; Claudia Ringhofer; Margit Eisler; Roland Sedivy; Fritz Wrba; Johannes Zacherl; Enrico P Cosentini; Gerhard Prager; Michael Haefner; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Comparison of long-term outcome of laparoscopic and conventional nissen fundoplication: a prospective randomized study with an 11-year follow-up.

Authors:  Paulina T P Salminen; Heikki I Hiekkanen; Arto P T Rantala; Jari T Ovaska
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

4.  Use of antireflux medication after antireflux surgery.

Authors:  Bas P L Wijnhoven; Carolyn J Lally; John J Kelly; Jennifer C Myers; David I Watson
Journal:  J Gastrointest Surg       Date:  2007-12-11       Impact factor: 3.452

5.  The end of robot-assisted laparoscopy? A critical appraisal of scientific evidence on the use of robot-assisted laparoscopic surgery.

Authors:  Jeroen Heemskerk; Nicole D Bouvy; Cor G M I Baeten
Journal:  Surg Endosc       Date:  2014-04       Impact factor: 4.584

6.  Four-year follow-up of endoscopic gastroplication for the treatment of gastroesophageal reflux disease.

Authors:  Matthijs P Schwartz; J Rieneke C Schreinemakers; André J P M Smout
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

7.  A Novel, Dynamic Statistical Model for Predicting Patient Satisfaction with Fundoplication Based on Pre-Operative Symptom Patterns.

Authors:  B L Woodham; R Meng; R H Roberts
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

8.  Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study.

Authors:  Pier Alberto Testoni; Sabrina Testoni; Giorgia Mazzoleni; Cristian Vailati; Sandro Passaretti
Journal:  Surg Endosc       Date:  2014-12-06       Impact factor: 4.584

Review 9.  Surgical reintervention after failed antireflux surgery: a systematic review of the literature.

Authors:  Edgar J B Furnée; Werner A Draaisma; Ivo A M J Broeders; Hein G Gooszen
Journal:  J Gastrointest Surg       Date:  2009-04-04       Impact factor: 3.452

10.  Risks of minimally invasive surgery underestimated: a report of the Dutch Health Care Inspectorate.

Authors:  Laurents P S Stassen; Willem A Bemelman; Jeroen Meijerink
Journal:  Surg Endosc       Date:  2009-07-22       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.